1-17 of 17
David John Lewis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Prospective Analysis of Outcomes Following Successive Lines of Treatment in Mantle Cell Lymphoma in an Unselected Previously Untreated Population: The UK MCL Biobank

Sarah Mant, Georgina Naylor, Nicola Crosbie, Sree Aroori, Mark J Bishton, Kristian Bowles, Safia Dawi, Toby A. Eyre, Wendy Ingram, Abigail Martin, Christopher McNamara, Melanie Oates, Andrew Pettitt, Claire Scully, Brian Wainman, Mark Warner, Simon Rule, David John Lewis
Journal: Blood
Blood (2024) 144 (Supplement 1): 1641.
https://doi.org/10.1182/blood-2024-209701
Published: 2024
Journal Articles

Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial

Steven Le Gouill, Virginie de Wilde, Toby A. Eyre, Mary B. Callanan, Gandhi Damaj, Alexis Claudel, Adrien Chauchet, Roch Houot, Ronan Le Calloch, Victoria Cacheux, Marc André, Franck Morschhauser, Barbara Burroni, David John Lewis, Benoit Tessoulin, Aurore Touzart
Journal: Blood
Blood (2024) 144 (Supplement 1): 745.
https://doi.org/10.1182/blood-2024-194357
Published: 2024
Journal Articles

Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Euan Haynes, Kushani Ediriwickrema, Sarah Lawless, Kevin Joyce, Matthew Wells, Jeffrey Smith, Kim Linton, Anna Santarsieri, George Follows, John Willan, Robert Osborn, Matthew R Wilson, Pamela McKay, Mahina Baloch, Rory McCulloch, Mary Gleeson, David Wrench, David Foldes, Edward Kanfer, Kyaw Zin Maw, Andrea Kuhnl, Matthew Ahearne, Mary Owen, Jane Norman, Ravindu De Silva, Nimish Shah, Harriet Ambrose, Christopher P. Fox, Janine Qasim, Graham P. Collins, Martha Vickers, David Tucker, Li Yuan Chan, Sunil Iyengar, Dima el-Sharkawi, Rebecca Auer, Catherine Cox, Hwai Jing Hiew, Andrew J. Davies, Philippa Kelsey, David John Lewis, Abigail Martin, Gavin Preston, Dominic J. Culligan, Angus Broom, William Wilson, Wendy Osborne, William Townsend
Journal: Blood
Blood (2024) 144 (Supplement 1): 3100.
https://doi.org/10.1182/blood-2024-203781
Published: 2024
Journal Articles

Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial

Yasmin H. Karimi, Michael Roost Clausen, David John Lewis, Wojciech Jurczak, Michelle Poon, Tae Min Kim, Young Rok Do, Pieternella Lugtenburg, Kristin Conte, David Soong, Barbara D'Angelo Månsson, Zhu Li, Christian Eskelund, Martin Hutchings
Journal: Blood
Blood (2024) 144 (Supplement 1): 1737.
https://doi.org/10.1182/blood-2024-199225
Published: 2024
Journal Articles

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

David John Lewis, Mats Jerkeman, Lexy Sorrell, David Wright, Ingrid Glimelius, Annika Pasanen, Jacob Haaber Christensen, Karin Fahl Wader, Andrew J. Davies, Nick Morley, Christopher McNamara, Christian Bjørn Poulsen, Jon Riise, Kristina Sonnevi, Ingemar Lagerlöf, Cathy Burton, Surita Dalal, Andrew Rawstron, Ruth M de Tute, Victoria Allgar, Sree Aroori, Mark Warner, Brian Wainman, Claire Scully, Jeanette Sanders, Carsten Utoft Niemann, Helle Toldbod, Nicola Crosbie, Mark J Bishton, Toby A. Eyre, Simon Rule
Journal: Blood
Blood (2024) 144 (Supplement 1): 235.
https://doi.org/10.1182/blood-2024-199710
Published: 2024
Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

M.Lia Palomba, Manish R. Patel, Toby A. Eyre, Wojciech Jurczak, David John Lewis, Thomas Gastinne, Shuo Ma, Jonathon B. Cohen, Krish Patel, Jennifer R. Brown, Lydia Scarfò, Talha Munir, Ewa Lech-Marańda, Marc Hoffmann, Chaitra S. Ujjani, Bita Fakhri, Michael L. Wang, Koji Izutsu, Hirokazu Nagai, Constantine S. Tam, John F. Seymour, Joanna M. Rhodes, Julie M. Vose, Matthew McKinney, James N. Gerson, Minal A. Barve, Bryone J. Kuss, Youngil Koh, Wei Gao, Amy S. Ruppert, Richard A. Walgren, Donald E. Tsai, Binoj Nair, Katherine Bao, Anthony R. Mato, Chan Y. Cheah
Journal: Blood
Blood (2022) 140 (Supplement 1): 557–560.
https://doi.org/10.1182/blood-2022-159123
Published: 2022
Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

William G. Wierda, David John Lewis, Paolo Ghia, Nirav N. Shah, Catherine C. Coombs, Chan Y. Cheah, Nicole Lamanna, Joanna M. Rhodes, Marc Hoffmann, Shuo Ma, Toby A. Eyre, Talha Munir, Manish R. Patel, Alvaro J. Alencar, Constantine S. Tam, John F. Seymour, Wojciech Jurczak, Ewa Lech-Marańda, Lindsey E. Roeker, Philip A. Thompson, Paolo B. Abada, Chunxiao Wang, Binoj Nair, Hui Liu, Donald E. Tsai, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 846–849.
https://doi.org/10.1182/blood-2022-157058
Published: 2022
Journal Articles

Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Jaimal Kothari, Toby A. Eyre, Ali Rismani, Helen McCarthy, Angela Collins, David John Lewis, Suzanne O Arulogun, William Wilson, Laura Clifton-Hadley, Darren Edwards, Kushani Ediriwickrema, Rebecca Auer, Guy Pratt, Ruth M. de Tute, Roger G Owen, Shirley D'Sa
Journal: Blood
Blood (2022) 140 (Supplement 1): 3624–3626.
https://doi.org/10.1182/blood-2022-167158
Published: 2022
Journal Articles

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Tycel Phillips, Catherine Thieblemont, Herve Ghesquieres, Chan Y. Cheah, Michael Roost Clausen, David Cunningham, Young Rok Do, Tatyana A. Feldman, Robin Gasiorowski, Wojciech Jurczak, Tae Min Kim, David John Lewis, Marjolein van der Poel, Michelle Limei Poon, Nurgul Kilavuz, Mariana Cota Stirner, David Soong, Christopher Chiu, Menghui Chen, Mariana Sacchi, Brian Elliot, Martin Hutchings, Pieternella Lugtenburg
Journal: Blood
Blood (2022) 140 (Supplement 1): 9443–9445.
https://doi.org/10.1182/blood-2022-158245
Published: 2022
Journal Articles

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew J Davies, Josh Caddy, Katy McLaughlin, Christopher Wignall, Robert Waugh, Graham P. Collins, Louise Stanton, Geoff N Saunders, Thomas Cummin, Anna Schuh, Kirit M. Ardeshna, Andrew K. McMillan, John Radford, David John Lewis, Adam R Coleman, Gareth Griffiths, Cathy Burton, Sharon Barrans, Peter Johnson
Journal: Blood
Blood (2022) 140 (Supplement 1): 9478–9479.
https://doi.org/10.1182/blood-2022-163499
Published: 2022
Journal Articles

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

Anthony R. Mato, John M. Pagel, Catherine C. Coombs, Nirav N. Shah, Nicole Lamanna, Tahla Munir, Ewa Lech-Marańda, Toby A. Eyre, Jennifer A. Woyach, William G. Wierda, Chan Yoon Cheah, Jonathon B. Cohen, Lindsey E. Roeker, Manish R. Patel, Bita Fakhri, Minal A. Barve, Constantine S. Tam, David John Lewis, James N. Gerson, Alvaro J. Alencar, Chaitra S. Ujjani, Ian W. Flinn, Suchitra Sundaram, Shuo Ma, Deepa Jagadeesh, Joanna M Rhodes, Justin Taylor, Omar Abdel-Wahab, Paolo Ghia, Stephen J. Schuster, Denise Wang, Binoj Nair, Edward Zhu, Donald Tsai, Matthew S. Davids, Jennifer R. Brown, Wojciech Jurczak
Journal: Blood
Blood (2021) 138 (Supplement 1): 391.
https://doi.org/10.1182/blood-2021-147599
Published: 2021
Journal Articles

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study

Michael Wang, Nirav N. Shah, Alvaro J. Alencar, James N. Gerson, Manish R. Patel, Bita Fakhri, Wojciech Jurczak, Xuan Ni Tan, Katharine Lewis, Timothy S. Fenske, Catherine C. Coombs, Ian W. Flinn, David John Lewis, Steven Le Gouill, M. Lia Palomba, Jennifer A. Woyach, John M. Pagel, Nicole Lamanna, Jonathon B. Cohen, Minal A. Barve, Paolo Ghia, Toby A. Eyre, Pier Luigi Luigi Zinzani, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, Ewa Lech-Marańda, Constantine S. Tam, Suchitra Sundaram, Ming Yin, Binoj Nair, Minna Balbas, Donald Tsai, Anthony R. Mato, Chan Yoon Cheah
Journal: Blood
Blood (2021) 138 (Supplement 1): 381.
https://doi.org/10.1182/blood-2021-149138
Published: 2021
Journal Articles

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study

Michael Wang, MD, Nirav N. Shah, MD, Alvaro J. Alencar, MD, James N. Gerson, MD, Manish R. Patel, MD, Bita Fakhri, MDMPH, Wojciech Jurczak, MD PhD, Xuan Ni Tan, MD, Katharine L Lewis, MBBS, Timothy S. Fenske, MD, Catherine C. Coombs, MD, Ian W. Flinn, MD PhD, David John Lewis, MD, Steven Le Gouill, MD PhD, M. Lia Palomba, MD, Jennifer A. Woyach, MD, John M. Pagel, MDPhD, Nicole Lamanna, MD, Jonathon B. Cohen, MDMS, Minal Barve, MD, Paolo Ghia, MD PhD, Toby A. Eyre, Ming Yin, Binoj Nair, PhD, Donald Tsai, MD PhD, Nora C. Ku, MD, Anthony Mato, MD, Chan Yoon Cheah, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–10.
https://doi.org/10.1182/blood-2020-134314
Published: 2020
Journal Articles

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Martin Hutchings, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, MD PhD, Peter Johnson, MD FRCP, Kim M Linton, MBChB, PhD, Martine E.D. Chamuleau, MD PhD, David John Lewis, MD, Anna Sureda Balari, MD PhD, David Cunningham, MD FRCP, FMedSci, Roberto S Oliveri, MD PhD, Dena DeMarco, Brian Elliott, MD, Kuo-mei Chen, PhD, Pieternella J. Lugtenburg, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-133820
Published: 2020
Journal Articles

Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew Davies, Josh Caddy, Katy Mercer, Geoff N Saunders, Louise Stanton, Graham P. Collins, MD DPhil, Thomas E C Cummin, MRCP MBBCh BSc, Anna Schuh, MD MRCP, PhD, Kirit M. Ardeshna, Andrew McMillan, John A. Radford, MD FMedSci, David John Lewis, MD, Adam Coleman, Gareth Griffiths, Cathy Burton, MBBChir, MA, MD FRCPath, Sharon Barrans, Peter Johnson, MD FRCP
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-134546
Published: 2020
Journal Articles

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

Anthony R. Mato, MD, John M. Pagel, MDPhD, Catherine C. Coombs, MD, Nirav N. Shah, MD, Nicole Lamanna, MD, Ewa Lech-Marańda, MD PhD, Toby A. Eyre, Jennifer A. Woyach, MD, William G. Wierda, MD PhD, Chan Yoon Cheah, MBBS, Lindsey E Roeker, MD, Manish R. Patel, MD, Bita Fakhri, MDMPH, Minal Barve, MD, Constantine S. Tam, MBBS, David John Lewis, MD, James N. Gerson, MD, Alvaro J. Alencar, MD, Justin Taylor, MD, Omar Abdel-Wahab, MD, Paolo Ghia, MD PhD, Stephen J. Schuster, MD, Jessica Chen, MS, Binoj Nair, PhD, Donald Tsai, MD PhD, Nora C. Ku, MD, Matthew S. Davids, MD, Jennifer R Brown, MD PhD, Wojciech Jurczak, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–37.
https://doi.org/10.1182/blood-2020-134970
Published: 2020
Journal Articles

AVAIL-T: A Phase 2a Trial of Avelumab, and Anti-PD-L1 Antibody, in Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL)

Matthew J Ahearne, Charlotte Gaskell, BSc, MSc, Aimee E Jackson, BSc, MSc, Clare Morland, PhD, Louise Hopkins, Nadia Nawaz, Matthew A Timmins, Christopher P Fox, MD PhD, Graham P. Collins, MD DPhil, Andrew Davies, David John Lewis, MD, Kate Cwynarski, Kim Linton, MBChB, MRCP, PhD, Pam McKay, MD, Rod Johnson, Simon D. Wagner
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-136061
Published: 2020